Laminin

Endothelial growth medium-2 (EGM-2) was obtained from Lonza (Walkersville, MD, USA). Minimum essential medium (MEM) and fetal bovine serum (FBS) were purchased from Invitrogen (Grand Island, NY, USA). Recombinant human vascular endothelial growth factor (VEGF₁₆₅), recombinant human basic fibroblast growth factor (bFGF) and laminin were obtained from Koma Biotech (Seoul, Korea). Matrigel and Transwell chamber systems were obtained from BD Biosciences (San Jose, CA, USA) and Corning Costar (Acton, MA, USA), respectively. Anti-hypoxia inducible factor-1α (HIF-1α) antibody was purchased from BD Biosciences. Anti-phospho-VEGFR2, anti-VEGFR2, anti-phospho-Akt, anti-Akt, anti-phospho-ERK1/2, anti-ERK1/2, anti-phospho-NFκB, anti-NFκB, anti-phospho-JNK, anti-JNK, anti-phospho-p38, anti-p38, anti-MMP-2, anti-MMP-9 and anti-β-actin antibodies were purchased from Cell Signaling Technology (Beverly, MA, USA).

Resveratrol and pterostilbene were purchased from Sigma-Aldrich (Saint Louis, MO, USA) and dissolved in dimethyl sulfoxide (DMSO) at a concentration of 100 mM to prepare a stock solution. Matrigel and gelatin were obtained from BD Biosciences (San Jose, CA, USA). Laminin and the Transwell chamber system were obtained from Koma Biotech (Seoul, Korea) and Corning Costar (Acton, MA, USA), respectively. Antibodies against p21, p53, MMP-2, MMP-9, Bcl-2, Bcl-XL, cleaved caspase-3, cleaved caspase-9, cyclin E1, cyclin B1, STAT3, phospho-STAT3, Sox2, Oct4, Nanog, β-actin, rabbit IgG, and mouse IgG were purchased from Cell Signaling Technology (Danvers, MA, USA). Anti-CD133 antibody was obtained from MiltenyiBiotec GmbH (BergischGladbach, Germany).